Article thumbnail

Appraisal of progenitor markers in the context of molecular classification of breast cancers

By Izhak Haviv

Abstract

Clinical management of breast cancer relies on case stratification, which increasingly employs molecular markers. The motivation behind delineating breast epithelial differentiation is to better target cancer cases through innate sensitivities bequeathed to the cancer from its normal progenitor state. A combination of histopathological and molecular classification of breast cancer cases suggests a role for progenitors in particular breast cancer cases. Although a remarkable fraction of the real tissue repertoire is maintained within a population of independent cell line cultures, some steps that are closer to the terminal differentiation state and that form a majority of primary human breast tissues are missing in the cell line cultures. This raises concerns about current breast cancer models

Topics: Editorial
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3109558
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). Ashworth A: Stem cells and breast cancer: a fi eld in transit. Nat Rev Cancer
  2. (2008). CJ: A for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med
  3. (2007). Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell
  4. (2008). H: Basal carcinoma of the breast revisited: an old entity with new interpretations. J Pathol
  5. (2006). JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell
  6. Kripke ML: Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet 2003, 34:23; author reply 25.
  7. (2009). Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med
  8. (2010). Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res
  9. (2003). MF: Prospective identifi cation of tumorigenic breast cancer cells.
  10. (2007). Molecular defi nition of breast tumor heterogeneity. Cancer Cell
  11. (2000). Molecular portraits of human breast tumours. Nature
  12. (2010). Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res
  13. (2008). RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell
  14. (2010). Reis-Filho JS, Smalley MJ: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell
  15. (2010). Reis-Filho JS: Breast cancer precursors revisited: molecular features and progression pathways. Histopathology
  16. (2009). Thiery JP: Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res